Proteasome Inhibitors Interact Synergistically with BCL2, Histone Deacetylase, BET, and Jak Inhibitors against Cutaneous T-Cell Lymphoma Cells
- PMID: 36642402
- DOI: 10.1016/j.jid.2022.12.017
Proteasome Inhibitors Interact Synergistically with BCL2, Histone Deacetylase, BET, and Jak Inhibitors against Cutaneous T-Cell Lymphoma Cells
Similar articles
-
JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL.Blood Adv. 2020 May 26;4(10):2213-2226. doi: 10.1182/bloodadvances.2020001756. Blood Adv. 2020. PMID: 32437546 Free PMC article.
-
Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.Haematologica. 2010 Apr;95(4):613-21. doi: 10.3324/haematol.2009.013870. Epub 2010 Feb 4. Haematologica. 2010. PMID: 20133897 Free PMC article.
-
Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDAC.J Invest Dermatol. 2021 Feb;141(2):364-373. doi: 10.1016/j.jid.2020.05.110. Epub 2020 Jun 27. J Invest Dermatol. 2021. PMID: 32603749 Free PMC article.
-
Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.Dermatol Clin. 2015 Oct;33(4):757-64. doi: 10.1016/j.det.2015.05.010. Epub 2015 Aug 29. Dermatol Clin. 2015. PMID: 26433847 Review.
-
HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.Future Med Chem. 2012 Mar;4(4):471-86. doi: 10.4155/fmc.12.6. Future Med Chem. 2012. PMID: 22416775 Review.
Cited by
-
Extranodal lymphoma: pathogenesis, diagnosis and treatment.Mol Biomed. 2023 Sep 18;4(1):29. doi: 10.1186/s43556-023-00141-3. Mol Biomed. 2023. PMID: 37718386 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical